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The nonpeptide AVE0991 is an agonist of the angiotensin-(1–7) (Ang-(1–7)) Mas receptor and is expected to be a putative new
drug for treatment of cardiovascular disease. However, the mechanisms involved in the antiproliferative eﬀects of AVE0991 are not
fully understood. We saw that the compound attenuated proliferation in an angiotensin II-induced rat vascular smooth muscle
cells(VSMC)proliferationmodel.Moreover,treatmentwithAVE0991(10
−5 mol/Lor10
−7 mol/L)signiﬁcantlyattenuatedreactive
oxygen species (ROS) production, phosphorylation of p38 MAPK, and dose-dependently (10
−8 to 10
−5 mol/L) inhibited Ang
II-induced VSMC proliferation. Meanwhile, heme oxygenase-1 (HO-1) expression increased in the AVE0991 + Ang II group
(10
−5 mol/Lor10
−6 mol/L).However,thebeneﬁcialeﬀectsofAVE0991werecompletelyabolishedwhentheVSMCwerepretreated
withA-779(10
−6 mol/L).Furthermore,treatmentwiththeHO-1inhibitorZnPPIXattenuated theinhibitoryeﬀectofAVE0991on
Ang II-induced p38MAPK phosphorylation. These results suggest that AVE0991 attenuates Ang II-induced VSMC proliferation in
a dose-dependent fashion and that this eﬀect is associated with the Mas/HO-1/p38 MAPK signaling pathway.
1.Introduction
Angiotensin-(1–7) (Ang-(1–7)) is a potent, endogenous
eﬀector hormone of the renin angiotensin system (RAS)
pathway. It can be formed directly from Ang I or Ang II, or
indirectly from Ang I, where Ang-(1–9) is produced in an
intermediate step [1]. Santos et al. demonstrated that a G-
protein-coupled receptor is the speciﬁc Ang-(1–7) receptor
in Mas-deﬁcient mice [2]. Previous studies have shown that
Ang-(1–7) has opposite eﬀects to Ang II, which induces
myocardial hypertrophy and ultimately cellular proliferation
[3, 4]. A-779 is a selective antagonist to the Ang-(1–7) Mas
receptor and can therefore prevent eﬀects of Ang-(1–7) by
preventing ligand/receptor interactions [5].
Because the Ang-(1–7) peptide is not resistant to pro-
teolytic enzymes, its clinical application is limited. Wiemer
et al. have shown that a nonpeptide compound (AVE0991)
produces similar eﬀects as Ang-(1–7) in biological systems
[6]. Previous studies have shown that AVE0991 ameliorated
hepatic ﬁbrosis in the bile-duct-ligated rat model and
improved myocardial ﬁbrosis induced by isoproterenol in
male Wistar rats [7, 8]. AVE0991 is an orally available
compound that has a wider clinical application and thus
could be a putative new drug for the treatment of cardio-
vascular disease. However, the antiproliferative mechanisms
of AVE0991 are still not fully understood.
Numerous studies have shown that Ang II plays a critical
role during proliferation in vascular smooth muscle cells2 International Journal of Hypertension
(VSMCs) [9–12]. The molecular and cellular mechanisms
underlying the Ang II-dependent processes in vascular
remodeling have not been fully elucidated. However, the
mitogen-activated protein kinase (MAPK) cascade, partic-
ularly the p38 MAP kinase, may play a role in mediating
responses that are related to cell growth and diﬀerentiation
[13]. Ang II is a well-known activator of this signaling
pathway.
Heme oxygenases (HOs), which catalyze the breakdown
of heme to equimolar quantities of carbon monoxide (CO),
biliverdin, and ferrous iron, are the rate-limiting enzymes
in heme degradation. These enzymes have antioxidative and
anti-inﬂammatory eﬀects, and several studies have suggested
that HO-1 has a cytoprotective role [14, 15]. Additionally,
many studies have indicated that HO-1 has a beneﬁcial
antiproliferative eﬀect in VSMCs and that this eﬀect can be
abolished by the HO-1 inhibitor ZnPPIX [16].
Moreover, Ang II-stimulated growth of VSMCs has an
essential redox-sensitive component that is mediated by
activation of MAPK-dependent signaling pathways, while
HO-1 attenuates the Ang II-induced damage in VSMCs [17].
In addition, Sun et al. have shown that HO-1 attenuated Ang
II-inducedVSMCsproliferationviainhibitingtheexpression
of MAPK [18]. Hence, we hypothesize that the HO-1/p38
MAPK signaling pathway may be involved in the inhibition
of VSMCs proliferation.
The objectives of this study were to determine whether
the nonpeptide compound AVE0991 could inhibit Ang II-
induced VSMCs proliferation and if the HO-1/p38 MAPK
signal pathways are involved in the AVE0991-mediated
eﬀects.
2.MaterialsandMethods
The investigation was carried out according to the Guide for
Care and Use of Laboratory Animals that was published by
the US National Institutes of Health (NIH Publication no.
85-23, revised in 1996).
2.1. Materials. The peptides Ang II and the Ang-(1–7) Mas
receptor antagonist A779 were obtained from Bachem (King
of Prussia, PA, USA). The β-actin monoclonal antibody
and HO-1 inhibitor ZnPPIX were obtained from Sigma-
Aldrich (St. Louis, MO, USA). Dulbecco’s modiﬁed Eagle
medium (DMEM) and trypsin were obtained from Invitro-
gen (Carlsbad, CA, USA). [3H]Thymidine (20Ci/mmol) was
obtainedfromtheAtomicEnergyInstituteofChina(Wuhan,
China). Fetal bovine serum (FBS) was purchased from
the Sijiqing Company (Hangzhou, China). AVE0991 was
kindly provided by Dr. Juergen Puenter of Aventis Pharma
(Frankfurt, Germany) and male Sprague-Dawley rats (10 to
12 weeks old) were obtained from the Experimental Animal
Facility of Sun Yat-sen University, China.
2.2. Cell Culture and Experimental Designs. VSMCs were
isolated from the thoracic aorta of 10- to 12-week-old male
Sprague-Dawley rats by an explant culture method. The
cells were seeded in DMEM/Ham’s F-12 (1:1) that was
(a)
(b)
Figure 1: The analysis of cultured VSMCs in morphology and
identiﬁcation. (a) The morphology of cultured VSMCs detected
by phase-contrast microscope. Magniﬁcation of light microscopy
images is ×100. (b) SM-α actin immunocytochemical staining of
culturedVSMCs.Magniﬁcationoflightmicroscopyimagesis ×400.
supplemented with 10% FBS, 100μg/mL penicillin, and
100U/mL streptomycin (Invitrogen). The cell preparations
were cultured at 37◦C in a humidiﬁed atmosphere with 5%
CO2. The culture purity was assessed by immunostaining
with a monoclonal antibody against smooth muscle α-actin,
followed by an anti-mouse ﬂuorescein-conjugated goat IgG
antibody. Usingthesemethods,thepurityofVSMCsreached
morethan98%. Cellsbetweenpassages4and7wereusedfor
all of the experiments [19]( Figure 1).
The cells were rendered quiescent by serum starvation
for 36 hours before ROS, HO-1, and p38 phosphorylation
detection, and for 48 hours before thymidine incorporation
experimentation. The VSMCs were treated according to the
following experimental protocols.
Protocol 1. Eﬀect of various concentrations of AVE0991 on
the VSMCs [3H]thymidine incorporation eﬃciency.
The cells were pretreated with Ang II for 24 hours
and then followed by AVE0991 (10−5 mol/L, 10−6 mol/L,
10−7 mol/L, or 10−8 mol/L) for 24 hours.
Protocol 2. Eﬀects of AVE0991 on Ang II-induced VSMC
proliferation, ROS production, HO-1 protein, and p38
phosphorylation expression.
For Ang II group, the cells were treated with Ang II for 48
hours.ForAngII+AVE0991-H(10−5 mol/L)groupandAng
II+AVE0991-L(10−7 mol/L)group,thecellswerepretreatedInternational Journal of Hypertension 3
with Ang II for 24 hours and followed by AVE0991 for 24
hours. And for Ang II + AVE0991-H (10−5 mol/L) + A-
779 group, the cells were pretreated with A-779 for 30min,
followed by Ang II for 24 hours, and then AVE0991 for 24
hours.
Protocol 3. Eﬀects of AVE0991 on Ang II-induced VSMCs
proliferation, ROS production, and p38 phosphorylation
expression with pretreatment of HO-1 inhibitor ZnPPIX.
F o rA n gI Igr o u p ,t h ec e ll sw e r etr e a t e dwi t hA n gI If o r4 8
hours. For Ang II + AVE0991 (10−5mol/L) group, the cells
were pretreated with Ang II for 32 hours and followed by
treatment with AVE0991 for 16 hours. For Ang II + AVE0991
(10−5 mol/L) + A-779 group, the cells were pretreated with
A-779 for 30min, then treated with Ang II for 32 hours,
and then followed by treatment with AVE0991 for 16 hours.
And for Ang II + AVE0991 (10−5 mol/L) + ZnPPIX group,
the cells were treated in the following order: Ang II for 24
hours, HO-1 inhibitor ZnPPIX for 8 hours, and AVE0991 for
16 hours.
2.3. [3H]Thymidine Incorporation. De novo DNA synthesis
was measured via incorporation of tritiated thymidine by
VSMCs that were grown in 24-well culture plates. The cells
were plated at a density of 2000cells/well and subconﬂuent
monolayers were made quiescent by serum starvation for
48h. The monolayers were then treated with or without
Ang II for 48h and were subsequently treated with various
concentrations of AVE0991, A-779, and/or ZnPPIX. During
the last 24h, 0.25μCi of [3H]thymidine/mL culture medium
was added to the growth medium. The incorporation of
[3H]thymidine was determined after precipitation of acid-
insoluble material with ice-cold 5% trichloroacetic acid. The
acid-insoluble material was dissolved in 0.25% NaOH and
counted in a liquid scintillation spectrometer in the presence
of 5mL Ecolite.
2.4. Detection of ROS Production. VSMCs were preloaded
with 30μmol/L 2 -7 -dichloroﬂuorescein diacetate at 37◦C
for 75min and were treated with the indicated agents for
an additional 2h in serum-free medium. After washing
with Hanks, the cells were lysed with Tris-HCl (10mmol/L,
pH 7.4, containing 0.5% Tween-20) and were centrifuged
at 10,000g for 10min. The ﬂuorescence intensity of the
supernatants was determined with a spectroﬂuorometer
[20].
2.5. Western Blotting. The cytosolic proteins were extracted,
and the total protein concentration was determined with a
BCA Protein Assay kit (Pierce, Rockford, IL, USA). Thirty
micrograms of crude protein extract was loaded on to a 10%
SDS-polyacrylamide gel and transferred to a polyvinylidene
ﬂuoride membrane. The membrane was blocked for 2h
at room temperature and incubated with an anti-HO-1
(1:1000 dilution; Santa Cruz Biotechnology, Santa Cruz,
CA, USA), anti-phosphorylated p38 or p38 (1:800 dilution;
Cell Signal, Beverly, MA, USA), or anti-GAPDH (1:10000
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Figure 2: The eﬀect of various concentrations of AVE0991 on the
VSMCs [3H]thymidine incorporation eﬃciency when stimulated
with Ang II. ∗P<0.05; ∗∗P<0.01 versus control group;  P<
0.05 versus Ang II + AVE0991 (10−6mol/L) group; n = 8.
dilution; Boshide, Wuhan, China) antibody diluted in Tris-
buﬀered saline/Tween-20 (TBS-T). After washing, the mem-
branes were subsequently incubated for 1h with rabbit
anti-mouse or goat anti-rabbit secondary antibodies diluted
1:2000 or 1:3000, respectively, in TBS-T. The bands were
visualized with an ECL kit (GE Healthcare, Chalfont St Giles,
Bucks, UK) according to the manufacturer’s instructions,
and GAPDH was used as a loading control. The results
were analyzed with a gel image analysis system (Bio-Rad,
Richmond, CA, USA).
2.6.StatisticalAnalysis. Thedataareexpressedasthemean ±
standard deviation (SD). Diﬀerences between groups were
evaluated by two-tailed unpaired Student’s t-test, and a value
of P<0.05 was interpreted as being statistically signiﬁcant.
Statistical analyses were performed using SPSS 13.0 statistics
software (SPSS Inc., Chicago, IL, USA).
3. Results
3.1. Eﬀects of AVE0991 on Ang II-Induced VSMC Proliferation
and ROS Production. Firstly, we evaluated the inhibition
eﬀect of AVE0991 on Ang II-induced VSMCs proliferation.
Ang II (10−6 mol/L) and AVE0991 (10−5 mol/L, 10−6 mol/L,
10−7 mol/L, or 10−8 mol/L) were added to culture ﬂuid.
The [3H]thymidine incorporation eﬃciency of VSMCs
was inhibited by AVE0991 in a dose-dependent manner
(Figure 2).
Secondly, treatment with 10−6 mol/L of Ang II signiﬁ-
cantly increased the [3H]thymidine incorporation eﬃciency
of VSMCs compared to the control group (n = 8, P<
0.01) (Figure 3). When the VSMCs were treated with the
same dose of Ang II combined with AVE0991 (10−5 mol/L
and10−7 mol/L),the[3H]thymidineincorporationeﬃciency
decreased signiﬁcantly when compared to the Ang II group
(n = 8, P<0.01), although the eﬃciency was still higher
than the control group. Nevertheless, when the cells were
treated with Ang II + AVE0991 + A-779 (10−6mol/L), this
AVE0991-mediated eﬀect which inhibited [3H]thymidine
incorporation eﬃciency of VSMCs was abolished. However,4 International Journal of Hypertension
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Figure 3: The eﬀect of AVE0991 on the [3H]thymidine incorpora-
tion eﬃciency of VSMCs that were stimulated by Ang II. ∗P<0.05;
∗∗P<0.01 versus control group;   P<0.01 versus Ang II group;
P<0.05 versus Ang II + AVE0991-H group; n = 8.
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Figure 4: The eﬀect of AVE0991 on Ang II-stimulated ROS
production in VSMCs. ∗P<0.05; ∗∗P<0.01 versus control group;
 P<0.01versusAngIIgroup; P<0.05versusAngII+AVE0991-
H group; n = 8.
when the VSMCs were treated with 10−5 mol/L AVE0991 or
10−6 mol/L A-779, both reagents aﬀected the [3H]thymidine
incorporation eﬃciency of the VSMCs. Compared to the
control group, the [3H]thymidine incorporation eﬃciency
was decreased when the cells were treated with AVE0991
alone (n = 8, P<0.05). Conversely, the eﬃciency increased
when the cells were treated with A-779 alone (n = 8, P<
0.05).
We sought to determine whether AVE0991 inhibition
of Ang II-stimulation has any eﬀect on ROS production
afterwards. The ROS level was signiﬁcantly increased in
the Ang II group (10−6 mol/L) compared to the con-
trol group (Figure 4). AVE0991 signiﬁcantly inhibited Ang
II-stimulated ROS expression, especially in the Ang II
(10−6 mol/L) + AVE0991-H (10−5 mol/L) group (n = 8, P<
0.01). However, neither AVE0991 nor A-779 alone had a
signiﬁcant eﬀect on ROS expression.
3.2. Eﬀects of AVE0991 on Ang II-Induced VSMC Proliferation
and ROS Production with Pretreatment of HO-1 Inhibitor
ZnPPIX. In this experiment, in the Ang II + AVE0991 +
ZnPPIX group, the [3H]thymidine incorporation eﬃciency
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Figure 5: The eﬀect of AVE0991 on the Ang II-induced VSMCs
[3H]thymidine incorporation eﬃciency with pretreatment with the
HO-1 inhibitor ZnPPIX. ∗∗P<0.01 versus control group;  P<
0.05;   P<0.05 versus Ang II group; P<0.01 versus Ang II +
AVE0991 group; n = 8.
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Figure 6: The eﬀect of AVE0991 on Ang II-stimulated ROS
production in VSMCs that were pretreated with the HO-1 inhibitor
ZnPPIX. ∗P<0.05; ∗∗P<0.01 versus control group;  P<0.01
versus Ang II group; P<0.01 versus Ang II + AVE0991 group;
n = 8.
of the VSMCs that were pretreated with ZnPPIX increased
signiﬁcantly when compared to the Ang II + AVE0991
(10−5 mol/L) group (n = 8, P<0.01), although the
eﬃciency was lower than the Ang II group (n = 8, P<0.05)
(Figure 5).
To determine whether AVE0991 inhibits Ang II-
stimulated ROS production via modulating HO-1 expres-
sion, we pretreated VSMCs with the HO-1 inhibitor ZnPPIX
(10−5 mol/L). The ROS level was signiﬁcantly higher in the
Ang II + AVE0991 (10−5 mol/L) + ZnPPIX group compared
to the Ang II + AVE0991 (10−5 mol/L) group (n = 8, P<
0.01). However, this AVE0991-mediated eﬀect was also
abolished by the Ang-(1–7) Mas receptor antagonist A-779
(Figure 6).
3.3. Eﬀect of AVE0991 on p38 Phosphorylation. The phos-
phorylation of p38 was signiﬁcantly higher in the Ang II
(10−6 mol/L) group compared to the control group (n = 8,
P<0.01) (Figure 7). AVE0991 treatment attenuated thisInternational Journal of Hypertension 5
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Figure 7: The eﬀect of AVE0991 on the p38 phosphorylation level
in VSMCs that were induced by Ang II. Lanes 1–7 represent the
control, AVE0991, A-779, Ang II, Ang II + AVE0991-H, Ang II +
AVE0991-H + A-779, and the Ang II + AVE0991-L group. ∗∗P<
0.01versuscontrolgroup;  P<0.01versusAngIIgroup; P<0.01
versus Ang II + AVE0991-H group; n = 8.
increase in p38 phosphorylation, and attenuation of p38
phosphorylation was more pronounced in the AVE0991
higher-concentration treatment group (AVE0991-H,
10−5 mol/L) compared to the AVE0991 low-concentration
treatment group (AVE0991-L, 10−7 mol/L). However,
when the cells were treated with Ang II + AVE0991 and
10−6 mol/L of A-779, there was no change in the level of p38
phosphorylation compared to the Ang II + AVE0991 group.
3.4. Eﬀect of AVE0991 on HO-1 Protein Expression. HO-1
proteinexpressionwasnotsigniﬁcantlydiﬀerentbetweenthe
Ang II (10−6 mol/L) and control groups (Figure 8). However,
AVE0991 treatment signiﬁcantly increased VSMCs HO-1
protein expression in the Ang II + AVE0991 group when
compared to the control group (n = 8, P<0.01). This
increase in HO-1 protein expression was more pronounced
in the AVE0991-H treatment group (10−5 mol/L) compared
tothe AVE0991-L treatmentgroup (10−7 mol/L) (n = 8, P<
0.05). However, when the cells were treated with Ang II +
AVE0991 (10−5 mol/L) + A-779 (10−6 mol/L), there was
no change in HO-1 expression compared to the Ang II +
AVE0991 (10−5 mol/L) group. Neither AVE0991 nor A-779
treatment alone has a signiﬁcant eﬀect on HO-1 protein
expression.
3.5. Eﬀect of AVE0991 on p38 Protein Phosphorylation When
the VSMC Were Pretreated with the HO-1 Inhibitor ZnPPIX.
We next sought to determine whether AVE0991 modulates
p38 phosphorylation via HO-1 expression. As Figure 9
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Figure 8: The eﬀect of AVE0991 on HO-1 protein expression in
VSMCs that were induced by Ang II. ∗P<0.01 versus control
group;  P<0.01 versus Ang II + AVE0991-H group; n = 8.
indicates, the level of p38 phosphorylation in the Ang II
(10−6 mol/L) group was signiﬁcantly higher than that in the
controlgroup.AVE0991treatment(10−5 mol/L)signiﬁcantly
inhibited Ang II-mediated p38 phosphorylation (n = 8,
P<0.01), although p38 phosphorylation was higher than
that in the control group (n = 8, P<0.01). However, when
the cells were pretreated with the HO-1 inhibitor ZnPPIX
(10−5 mol/L), the p38 phosphorylation level in the Ang II +
AVE0991 + ZnPPIX group was signiﬁcantly higher than that
in the Ang II + AVE0991 group (n = 6, P<0.01), although
the phosphorylation level was lower than that in the Ang II
group.
4. Discussion
The major ﬁnding of this study is that AVE0991, a nonpep-
tide analog of Ang (1–7), attenuates Ang II-induced VSMCs
proliferation by inducing heme oxygenase-1 expression and
by downregulating p-38 MAPK phosphorylation. In addi-
tion, the present study shows that AVE0991 suppresses the
Ang II-stimulated ROS production in VSMCs. Furthermore,
experiments with the HO-1 inhibitor ZnPPIX indicate
that AVE0991 decreases p-38 MAPK phosphorylation via
induction of HO-1 protein expression in Ang II-induced
VSMCs proliferation. In addition, treatment with AVE0991
attenuated proliferation of the VSMCs in a dose-dependent
manner. However, all of the beneﬁcial eﬀects of AVE0991
werecompletelyblockedbypretreatmentwiththeAng-(1–7)
receptor antagonist A-779.6 International Journal of Hypertension
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Figure 9: The eﬀect of AVE0991 on the p38 phosphorylation level
in VSMCs when combined with the HO-1 inhibitor ZnPPIX. ∗∗P<
0.01versuscontrolgroup;  P<0.01versusAngIIgroup; P<0.01
versus Ang II + AVE0991 group; n = 8.
AVE0991 mimics many of the biological actions of Ang-
(1–7) and acted like an Ang-(1–7) Mas receptor agonist
in Mas-knockout mice and Mas-transfected cells [1, 2,
6, 21]. Ang-(1–7) has been shown to improve vascular
endothelial dysfunction, delay the development of cardiac
hypertrophy, and attenuate the development of heart failure
[3, 22]. EJ Freeman reported that Ang-(1–7) pretreatment
also inhibited the proliferative eﬀects of Ang II-treated
VSMCs as measured by [3H]leucineincorporationand[3H]-
Thymidine incorporation [19]. Thus, Ang-(1–7) interacts
with speciﬁc receptors on VSMCs to exert antiproliferative
eﬀects that can reverse the Ang II-mediated eﬀects [19].
H o w e v e r ,b e c a u s ei ti sap e p t i d et h a ti sr a p i d l yd e g r a d e d
whenorallyadministered,Ang-(1–7)haslimitedclinicaluse.
In contrast, AVE0991, the nonpeptide analog of Ang-(1–7),
is resistant to proteolytic enzymes and can thus be clinically
oral applied to treat cardiovascular and related diseases.
Previous studies have shown that Ang II plays an
important role in VSMCs proliferation [10, 12]. In vitro,
Ang II is one of the most important factors that contribute
to VSMCs proliferation by increasing protein and DNA
synthesis through the type 1 Ang II receptor [23]. Because
Ang II induces a signiﬁcant increase in VSMCs protein
synthesis in conditioned medium [24], the VSMCs were
starved in DMEM medium without FBS for 36h in our
experiments to minimize the medium-induced myocyte
proliferative eﬀects. According to our previous studies and
other published results, the cells were starved for 48 hours
prior [3H]-Thymidine incorporation experiments [19]. In
addition,aVSMCspurityofgreaterthan98%wascontrolled
in every experiment group to decrease false results that could
be caused by contamination.
The present study indicates that Ang II promotes VSMCs
DNA synthesis (measured via [3H]-Thymidine incorpora-
tion) in vitro compared to the control group, which agrees
with the previously published ﬁndings. Treatment with
AVE0991 + Ang II signiﬁcantly suppressed DNA synthesis.
Moreover,whentheconcentrationofAVE0991wasincreased
from 10−8 mol/L to 10−5 mol/L, AVE0991 inhibited the Ang
II-mediated increase in DNA synthesis of the VSMCs in
a dose-dependent manner. When the cells were pretreated
with the Ang-(1–7) Mas receptor antagonist A-779, the
beneﬁcialeﬀectofAVE0991wascompletelyabolished,which
also suggested that the AVE0991 is a nonpeptide Mas
receptor agonist. In addition, treatment with AVE0991 alone
signiﬁcantly suppressed VSMCs DNA synthesis. Conversely,
A-779 alone also elicited a signiﬁcant increase in DNA
synthesis. However, diﬀerently to the results that were seen
with DNA synthesis, neither treatment with AVE0991 alone
nortreatmentwithA779alonecanalterROSproductionand
p38 phosphorylation. Future studies are needed to conﬁrm
these results.
Although AVE0991 treatment is antiproliferative in
VSMCs, the mechanisms of this eﬀect remain unclear.
Previous studies have shown that Ang II activates the
NAD(P)H oxidase enzyme system and promotes the gener-
ation of ROS, such as the superoxide anion and hydrogen
peroxide which stimulate smooth muscle cell proliferation
[10, 11, 25]. In addition, the mitogen-activated protein
kinasecascade,particularlyp38MAPK,maybeanimportant
intracellular mediator of responses that are related to cell
growth and diﬀerentiation [18] ;A n gI Ii saw e l l - k n o w na c t i -
vator of this signaling pathway. According to this evidence,
we question whether AVE0991 inhibits Ang II-stimulated
VSMCs proliferation by modulating ROS production or by
modulating the p38 pathway. In our study, Ang II promoted
ROS production compared to the control group. However,
treatment with AVE0991 signiﬁcantly suppressed Ang II-
mediated ROS production in a dose-dependent manner.
Similarly, the nonpeptide AVE0991 also inhibited Ang
II-mediated phosphorylation of p38MAPK. Nevertheless,
pretreatment with the Ang-(1–7) Mas receptor antagonist
A-779 also abolished the inhibitory eﬀects of AVE0991.
Hence, the present study shows that AVE0991 may inhibit
Ang II-mediated VSMCs proliferation by decreasing ROS
production and altering the p38 pathway. However, as an
important intracellular second messenger, ROS can activate
many downstream signaling molecules, including MAPK;
thus, there may be a relationship between the ROS and p38
mechanisms of AVE0991. Nevertheless, more direct evidence
should be established to fully understand these mechanisms.
Recently, induction of heme oxygenase- (HO-) 1 expres-
sion in vivo has been reported to suppress NADPH oxidase-
derived oxidative stress. Additionally, HO-1 overexpression
suppressed the Ang II-induced hypertrophic response in
cardiomyocytes via decreasing the ROS production stress
[20]. Ang II-stimulated growth of VSMCs has an essential
redox-sensitive component that is mediated by activation ofInternational Journal of Hypertension 7
the MAPK-dependent signaling pathways [26]. In addition,
HO-1 attenuates Ang II-induced VSMCs proliferation that
involves MAPK inhibition [18]. In neutrophils, HO-1 atten-
uates inﬁltration during sepsis via inactivation of p38 MAPK
[27]. Hence, we wonder whether there is any relationship
between HO-1 and p38 MAPK in Ang II-induced VSMCs
proliferation with AVE0991 treatment. In the present study,
the nonpeptide AVE0991 dose-dependently increased HO-
1 protein expression in the Ang II + AVE0991 group.
However, Ang II alone has no signiﬁcant eﬀect on HO-
1 protein expression, which agrees with the previous data
in cardiomyocytes [20]. In addition, pretreatment with
the HO-1 inhibitor ZnPPIX signiﬁcantly attenuated the
inhibitory action of AVE0991 on Ang II-induced VSMCs
DNA synthesis, which indicates that AVE0991 inhibits Ang
II-induced VSMCs proliferation partly via induction of HO-
1. On the other hand, ZnPPIX pretreatment signiﬁcantly
increasedtheAngII-inducedp38phosphorylationlevel.This
indicates that AVE0991 attenuates phosphorylation of p38
partly via induction of HO-1 expression in Ang II-induced
VSMCs proliferation.
In summary, our results suggest that the ACE2-Ang-(1–
7)-Mas pathway may play a more important antiproliferative
role than our current understanding of endogenous Ang-
(1–7) in RAS. Moreover, Ang II treatment upregulates
p38 phosphorylation and ROS production, which con-
tribute to VSMCs proliferation. Treatment with AVE0991
attenuates Ang II-induced VSMCs proliferation in a dose-
dependent manner, which may be associated with regulation
of Mas/HO-1/p38 signaling pathway.
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